Corcept Therapeutics Incorporated Stock Alpha and Beta Analysis
| CORT Stock | USD 50.86 0.89 1.78% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Corcept Therapeutics Incorporated. It also helps investors analyze the systematic and unsystematic risks associated with investing in Corcept Therapeutics over a specified time horizon. Remember, high Corcept Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Corcept Therapeutics' market risk premium analysis include:
Beta 1.17 | Alpha 0.14 | Risk 2.81 | Sharpe Ratio 0.0885 | Expected Return 0.25 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Corcept |
Corcept Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Corcept Therapeutics market risk premium is the additional return an investor will receive from holding Corcept Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Corcept Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Corcept Therapeutics' performance over market.| α | 0.14 | β | 1.17 |
Corcept Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Corcept Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Corcept Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Corcept Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Corcept Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Corcept Therapeutics shares will generate the highest return on investment. By understating and applying Corcept Therapeutics stock market price indicators, traders can identify Corcept Therapeutics position entry and exit signals to maximize returns.
Corcept Therapeutics Return and Market Media
The median price of Corcept Therapeutics for the period between Sun, Oct 6, 2024 and Sat, Jan 4, 2025 is 52.14 with a coefficient of variation of 9.55. The daily time series for the period is distributed with a sample standard deviation of 5.0, arithmetic mean of 52.34, and mean deviation of 4.33. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Recent Price Trend in Corcept is Your Friend, Heres Why | 11/04/2024 |
2 | Disposition of 30000 shares by Guyer William of Corcept Therapeutics at 19.26 subject to Rule 16b-3 | 11/13/2024 |
3 | Acquisition by Gary Robb of 1818 shares of Corcept Therapeutics subject to Rule 16b-3 | 11/22/2024 |
4 | Disposition of 182 shares by Atabak Mokari of Corcept Therapeutics at 57.68 subject to Rule 16b-3 | 12/02/2024 |
5 | Disposition of 2200 shares by Swisher Daniel N Jr of Corcept Therapeutics at 59.46 subject to Rule 16b-3 | 12/10/2024 |
6 | Corcept Phase 2 study of ALS drug fails to meet primary endpoint | 12/11/2024 |
7 | Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism and Difficult-to-Control Diabetes | 12/12/2024 |
8 | Corcept Therapeutics FDA-Approved Korlym Hits Main Goal In Cushings Syndrome Patients With Difficult-To-Control Diabetes | 12/13/2024 |
9 | CTLA-4 Inhibitors Market to Advance at Moderate CAGR During the Study Period DelveInsight | 12/16/2024 |
10 | Geode Capital Management LLC Purchases 99,470 Shares of Corcept Therapeutics Incorporated | 12/19/2024 |
11 | Disposition of 7800 shares by Wilson James N of Corcept Therapeutics subject to Rule 16b-3 | 12/27/2024 |
12 | Corcept Submits Application for Another Cushings Syndrome Drug | 12/31/2024 |
About Corcept Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Corcept or other stocks. Alpha measures the amount that position in Corcept Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Payables Turnover | 0.45 | 0.37 | 0.34 | 0.42 | Days Of Inventory On Hand | 1.2K | 435.34 | 500.64 | 475.61 |
Corcept Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Corcept Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Corcept Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Corcept Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Corcept Therapeutics. Please utilize our Beneish M Score to check the likelihood of Corcept Therapeutics' management manipulating its earnings.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Corcept Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Corcept Stock Analysis
When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.